ONC launches cardiovascular app challenge

Luke Gale | | Health Imaging | Oncology Imaging
Tablet Physician - 50.55 Kb
The Office of the National Coordinator for Health IT (ONC) announced a developer challenge aimed at reducing cardiovascular disease.

Developers are being asked to build a mobile application (app) that can engage those at risk, direct them to community health centers and motivate them to take action.

Apps should include an eight question health risk assessment survey outlined by the ONC. To help them complete the task, competitors are being granted access to an application programming interface for conducting risk assessments, and a database of lipid and blood pressure screening locations.

Submissions to the challenge, which will grant $5,000 to up to five finalists, are due by Oct. 31. Complete guidelines are available here.

Luke Gale

Related Content

New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection
VI-RADS threshold, imaging features predict bladder cancer invasiveness with nearly 100% accuracy
PHOTO GALLERY: thyroid nodule imaging
Tiny 'water bears' may hold key to reducing radiation-induced side effects
High-intensity focused ultrasound could allow prostate cancer patients to avoid surgery

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.